Lilly launches Tanstrive (Selpercatinib), a RET inhibitor to treat advanced cancers with RET gene… EP News Bureau Jun 25, 2026 Available in India in 40 mg, 80 mg, 120 mg and 160 mg tablet strengths; administered orally twice daily
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers EP News Bureau Dec 2, 2020 Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations
